Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8131 to 8145 of 8901 results

  1. The clinical effectiveness and cost effectiveness of tension-free vaginal tape for stress incontinence (TA56)

    This guidance has been updated and replaced by NICE guideline CG40. [Replaced by NICE guideline CG171 (September 2013)] 

    Withdrawn guidance

  2. Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)

    This guidance has been updated and replaced by NICE technology appraisal guidance 898.

    Withdrawn guidance

  3. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (TA567)

    This guidance has been updated and replaced by NICE technology appraisal guidance 933. People already having tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies through the Cancer Drugs Fund can continue. For those people, it will be funded by the company until they and their NHS clinician consider it appropriate to stop.

    Withdrawn guidance

  4. The clinical effectiveness and cost effectiveness of insulin pump therapy (TA57)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 151.

    Withdrawn guidance

  5. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA573)

    This guidance has been updated and replaced by NICE technology appraisal guidance 897.

    Withdrawn guidance

  6. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505)

    This guidance has been updated and replaced by NICE technology appraisal guidance 870.

    Withdrawn guidance

  7. Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)

    We have withdrawn this guidance. Grünenthal has stopped marketing Lesinurad (Zurampic) for commercial reasons and its marketing authorisation has been withdrawn.

    Withdrawn guidance

  8. Computerised cognitive behaviour therapy (CCBT) for the treatment of depression and anxiety (TA51)

    This guidance has been updated and replaced by NICE technology appraisal guidance 97.

    Withdrawn guidance

  9. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA510)

    This guidance has been updated and replaced by NICE technology appraisal guidance 783.

    Withdrawn guidance

  10. Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

    This guidance has been updated and replaced by NICE technology appraisal guidance 555.

    Withdrawn guidance

  11. Liquid-based cytology for cervical screening (TA5)

    This guidance has been replaced by NICE technology appraisal guidance 69.

    Withdrawn guidance

  12. Imanitib for chronic myeloid leukaemia (TA50)

    This guidance has been updated and replaced by NICE technology appraisal guidance 70 [Partially updated by NICE technology appraisal guidance 241].

    Withdrawn guidance

  13. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA578)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA798.

    Withdrawn guidance

  14. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    This guidance has been replaced by NICE's technology appraisal guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Withdrawn guidance

  15. Flu treatment - zanamivir, amantadine and oseltamivir (TA58)

    This guidance has been updated and replaced by NICE technology appraisal guidance 168.

    Withdrawn guidance